Chronic GVHD (cGVHD) is a major complication for nearly half of allogeneic hematopoietic SCT (HSCT) survivors. 1 Chronic GVHD is derived from, and is primarily mediated by, graftedimmunocompetent T cells that proliferate in the recipients and reject host cells as foreign, resulting in multi-organ dysfunction. Approximately 80% of patients with cGVHD have oral involvement characterized by erythema, lichen planus, hyperkeratotic plaques, pseudomembranes and ulcers. 2 Oral cGVHD-related pain is reported frequently, and oral dryness has been associated with inferior health-related quality of life. Thalidomide has shown efficacy and safety with minimal systemic absorption for treatment of aphthous stomatitis in HIV ( þ ) patients. 3 Here we report preliminary data for topical thalidomide gel in the management of oral ulcerative cGVHD.
This phase II, randomized, placebo-controlled, double-blind clinical trial evaluated the impact of thalidomide on patients with oral cGVHD. The protocol was proved by IRB at National Institute of Dental and Craniofacial Research, NIH. Enrolled into the study were 10 subjects whose ages ranged from 27 to 60 years, averaging 46 years. All 10 subjects had previously received allogeneic HSCT, who had histopathologically confirmed oral cGVHD consistent with the diagnostic criteria. All subjects had previously used a variety of oral agents to treat their oral cGVHD without resolution. Subjects were randomized to receive either thalidomide or placebo, and were instructed in administration of topical thalidomide gel 20 mg or placebo 4 times daily for 4 weeks to a maximum of three target oral ulcers. The response to thalidomide was measured by evaluating clinical performance and biological characteristics, including the healing rate of oral ulcers, pain intensity (sensory and affective pain) and concentration of cytokines in oral fluids. A Wilcoxon test was used to determine the difference between oral fluid cytokine levels at baseline and week 4. SAS version 9.2 and SPSS version 15.0 were used for the statistical analysis.
Of the 10 subjects, 6 completed the entire clinical trial, 3 each in the placebo and thalidomide groups. No serious adverse events occurred. Although the small sample size precluded statistical confirmation of topical thalidomide's efficacy for oral ulcerative cGVHD, the 66% mean percentage decrease in total surface area of oral ulceration at week 4 compared with baseline suggests single-agent activity of thalidomide gel. The 59% mean decrease in oral ulcerations' total surface area was higher than anticipated and may represent a placebo effect of the Orobase plain product or the waxing and waning nature of cGVHD. After the first 7 days of thalidomide treatment, tumor necrosis factor alpha (TNFa) levels in saliva and ulcer exudates decreased from baseline, then rose at week 3 ( Figure 1 ). Although TNFa levels in saliva and ulcer exudates decreased at week 4, there was no significant difference in these salivary levels compared with baseline for the thalidomide (P ¼ 1.0) or placebo (P ¼ 0.109) group. Compared with baseline, there was a decrease in the salivary IL6 concentration in the thalidomide group (P ¼ 0.465), but no decrease in the placebo group (Figure 1) .
The cytokine TNFa has a role, via the local inflammatory response, in oral cGVHD pathogenesis, which may be modified by topical thalidomide. 4, 5 TNFa levels in saliva and exudates dropped substantially after the first week of thalidomide treatment. After treatment completion (week 4), TNFa levels began to rise again, although the levels never increased to pretreatment baseline. This pattern of TNFa levels in the topical thalidomide group may be related to the activation of NFkB, which is initiated by signalinduced degradation of IkB proteins that normally sequester NFkB in the cytoplasm of oral inflammatory cells. NFkB translocates to the nucleus and activates gene expression for TNFa and IkBa. 6 The newly synthesized IkBa then re-inhibits NFkB, thus forming an auto-feedback loop. Although thalidomide suppresses TNFa production, it may also reduce the levels of newly synthesized IkBa, which may explain why TNFa levels began a gradual increase after 1 week of treatment. In the thalidomide group, both sensory and affective pain had decreased from baseline to week 4, although there was not a notable decrease in overall oropharyngeal pain intensity. Interestingly, the placebo group also reported a decrease in overall oropharyngeal pain intensity (Figure 2 ). The standardized area under the curve (AUC) in respect to baseline was used instead of the entire AUC to adjust for the oropharyngeal pain difference of baseline value and duration of 4 week's treatment among the subjects. The thalidomide and placebo groups' AUC showed no significant difference. However, there was a trend toward a reduction in pain intensity with swallowing in the thalidomide group compared with the placebo group (P ¼ 0.079).
The median sensory oral pain scores were consistently higher than the affective pain scores at all data collection time points for both thalidomide and placebo groups, suggesting an oral cGVHD pain phenotype. The lack of oropharyngeal pain in the thalidomide group at weeks 2 and 3 corresponded to a decrease in salivary and oral ulcer exudate TNFa levels from baseline. In the thalidomide group, oral pain scores, when compared with baseline, also decreased at week 4 and increased at week 8, paralleling TNFa expression in oral fluids. This observation suggests that (1) thalidomide reduced pain, and (2) monitoring TNFa may be useful to predict disease and related pain response in patients with oral cGVHD. 7 Objective and subjective responses of three patients treated with topical thalidomide outperformed those of three patients taking placebo. In the thalidomide group, a decrease was detected in ulcer size, pain intensity and cytokine expression in oral mucosa. TNFa and IL6 concentrations in oral fluids and oral tissue allowed quantification of cytokines in real time from the most severe presentation of oral cGVHD. 8 Topical thalidomide therapy appears to be effective in relieving oropharyngeal pain, and decreasing TNFa and IL6 expression levels in oral saliva, and oral ulcer exudates in patients with oral cGVHD. These preliminary results suggest single agent-activity of topical thalidomide gel for oral cGVHD and warrant additional studies evaluating the efficacy of this agent in oral cGVHD. 
